210P Precision immuno-oncology strategies to overcome drug resistance in non-small cell lung cancer

Lung cancer is a major public health issue and the leading cause of cancer-related mortality. Despite recent advances in non-small cell lung cancer (NSCLC) treatment, drug resistance and variable treatment responses remain significant challenges. These issues are driven by tumor heterogeneity and diverse immune responses, leading to treatment failure. Our research addresses these challenges by investigating intrinsic resistance mechanisms and developing precision tools to enhance therapeutic strategies.